Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
AssigneeOmeros Corporation
InventorsW. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
Life of this patent
Estimating the term…
Abstract
The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
Claims19
An isolated antibody, or antigen-binding fragment thereof, that binds to human MASP-3 comprising:
- a heavy chain variable region comprising a HC-CDR1 set forth as SEQ ID NO:72 (SYGMS) a HC-CDR2 set forth as SEQ ID NO:74 (WINTYSGVPTYADDFKG);
- and a HC-CDR3 set forth as SEQ ID NO:76 (GGEAMDY);
- and a light chain variable region comprising a LC-CDR1 selected from the group consisting of SEQ ID NO:153 (KSSQSLLDSDGKTYLN), SEQ ID NO:261 (KSSQSLLDSEGKTYLN), SEQ ID NO:262 (KSSQSLLDSAGKTYLN) and SEQ ID NO:263 (KSSQSLLDSDAKTYLN);
- a LC-CDR2 set forth as SEQ ID NO:155 (LVSKLDS);
- and a LC-CDR3 set forth as SEQ ID NO:157 (WQGTHFPWT).
An isolated antibody or antigen-binding fragment thereof that binds to human MASP-3, comprising a heavy chain variable region selected from the group consisting of SEQ ID NO:28, SEQ ID NO:251 and SEQ ID NO:252 and a light chain variable region selected from the group consisting of SEQ ID NO:43, SEQ ID NO:253 and SEQ ID NO:279.
Dependencies are inferred from the claim text.